METS - Message Evaluation and Testing Service | CDC


The Message Evaluation and Testing Service (METS) is designed to assist public health agencies in validating messages against the applicable messaging, vocabulary, and programmatic standards as they prepare to send high-quality electronic case notifications to the National Notifiable Diseases Surveillance System (NNDSS).

Welcome MQF Users

The Message Evaluation and Testing Service (METS) application now provides the same message validation capabilities as the Message Quality Framework (MQF) application. METS supports case notification, meaningful use, and PHLIP message specifications that were part of MQF. You can find a full listing of specifications currently supported by METS below. Additionally, if you were accustomed to using sample messages, you may still do so in METS. Like with MQF, you have the option to either validate your message or select from samples made available on the METS Message Validation page. For questions or support, contact

Final MMG Specifications

  • Arboviral v1.3
  • Babesiosis v1.0
  • Congenital Rubella Syndrome (CRS) v1.0 – pilot
  • Congenital Syphilis v1.0, v1.0.1, v1.1
  • COVID-19 v1.0
  • Foodborne and Diarrheal Disease (FDD) v1.0
  • Generic v2.0
  • Healthcare-associated infections / Multi-drug resistant organisms (HAI MDRO) v1.0
  • Hepatitis v1.0
  • Lyme/Tickborne Rickettsial Diseases (TBRD) v1.0
  • Malaria v1.0
  • Measles v1.0 – pilot
  • Mumps v1.0
  • Pertussis v1.0
  • Respiratory and Invasive Bacterial Disease (RIBD) v1.0 – pilot
  • Rubella v1.0 – pilot
  • Sexually Transmitted Diseases (STD) v1.0.1, v1.0.2, v1.1
  • Trichinellosis v1.0
  • Tuberculosis (TB) and Latent TB Infection (LTBI) v3.0
  • Varicella v3.0

PHLIP Specifications

  • PHLIP VPD v1.0
  • PHLIP ORU v1.0.2

Meaningful Use Specifications

Meaningful Use-Electronic Laboratory Reporting Sender Profile
  • ELR_ORU_R01_HL7_2.5.1_SP
Meaningful Use-Immunization HL7 2.3.1
  • IIS_VXU_V04_HL7_2.3.1
  • IIS_VXQ_V01_HL7_2.3.1
  • IIS_VXR_V03_HL7_2.3.1
  • IIS_VXX_V02_HL7_2.3.1
  • IIS_VXU_V04_HL7_2.3.1_ACK
  • IIS_VXQ_V01_HL7_2.3.1_ACK
  • IIS_VXQ_V01_HL7_2.3.1_QCK
Meaningful Use-Immunization HL7 2.5.1
  • IIS_VXU_V04_HL7_2.5.1
  • IIS_QBP_Q11_HL7_2.5.1
  • IIS_RSP_Z31_HL7_2.5.1
  • IIS_RSP_Z32_HL7_2.5.1
  • IIS_VXU_V04_HL7_2.5.1_ACK
  • IIS_QBP_Q11_HL7_2.5.1_ACK
  • IIS_RSP_Z11_HL7_2.5.1_ACK
Meaningful Use-Syndromic Surveillance HL7 2.3.1
  • Syndromic_ADT_A01_HL7_2.3.1
  • Syndromic_ADT_A03_HL7_2.3.1
  • Syndromic_ADT_A04_HL7_2.3.1
  • Syndromic_ADT_A08_HL7_2.3.1
  • Syndromic_ADT_A01_HL7_2.3.1_ACK_2.3.1
  • Syndromic_ADT_A03_HL7_2.3.1_ACK_2.3.1
  • Syndromic_ADT_A04_HL7_2.3.1_ACK_2.3.1
  • Syndromic_ADT_A08_HL7_2.3.1_ACK_2.3.1
Meaningful Use-Syndromic Surveillance HL7 2.5.1
  • Syndromic_ADT_A01_HL7_2.5.1
  • Syndromic_ADT_A03_HL7_2.5.1
  • Syndromic_ADT_A04_HL7_2.5.1
  • Syndromic_ADT_A08_HL7_2.5.1
  • Syndromic_ADT_A01_HL7_2.5.1_ACK_2.5.1
  • Syndromic_ADT_A03_HL7_2.5.1_ACK_2.5.1
  • Syndromic_ADT_A04_HL7_2.5.1_ACK_2.5.1
  • Syndromic_ADT_A08_HL7_2.5.1_ACK_2.5.1

Historical Specifications

  • Arboviral v1.2
  • Generic v1.0
  • Tuberculosis v2.0
  • Varicella v2.0